Fly News Breaks for June 25, 2019
Jun 25, 2019 | 08:37 EDT
After Abbvie (ABBV) announced an agreement to acquire Allergan (AGN) for $120 per share of cash and a remaining $68 in AbbVie shares, Wells Fargo analyst David Maris said he views the deal as a good alternative for Allergan versus the current share price, but he is not convinced its a better long term alternative given the eventual biosimilar threat to Abbvie's blockbuster drug Humira. With that said, Maris tells investors that "deals at such premiums are rarely killed because of a bad strategic fit or longer -term value outlook in the absence of other bidders." Though he would not completely rule out an activist investor disrupting the deal, he thinks it is unlikely given there has been a strategic review of the company for some time. Maris, who said he thinks the deal could go through, keeps an Outperform rating on Allergan shares.
News For AGN;ABBV From the Last 2 Days
There are no results for your query AGN;ABBV